使用实验性GIR数据识别PK-PD胰岛素模型
Identification of PK-PD Insulin Models using Experimental GIR Data
AI总结:
提出结合实验性GIR数据与PK-PD模型估计人体葡萄糖胰岛素动力学参数的方法,修改Hovorka模型并验证速效胰岛素类似物参数,探讨其在自动胰岛素给药系统中的应用。
摘要:
我们提出了一种方法,用于估计人体葡萄糖胰岛素动力学中药代动力学(PK)和药效学(PD)模型的参数。该方法结合了1)来自葡萄糖钳夹研究的实验性葡萄糖输注率(GIR)数据,以及2)一个PK-PD模型来估计参数,使得模型拟合数据。假设葡萄糖钳夹是完美的,我们不需要知道钳夹中控制器的细节,GIR可以直接从PK-PD模型计算得出。为了说明该过程,我们使用由Hovorka开发的葡萄糖调节模型,并对其进行修改,使其具有平滑的非负内源性葡萄糖产生(EGP)项。我们估计了速效胰岛素类似物(Fiasp和NovoRapid)的PK-PD参数。我们使用这些PK-PD参数来说明吸收时间比现有速效胰岛素类似物快30%和50%的胰岛素类似物的GIR。我们讨论了使用来自葡萄糖钳夹研究的GIR数据进行系统辨识的作用,以及此类已识别模型如何用于带有超速效胰岛素的自动胰岛素给药(AID)系统。
英文摘要:
We present a method to estimate parameters in pharmacokinetic (PK) and pharmacodynamic (PD) models for glucose insulin dynamics in humans. The method combines 1) experimental glucose infusion rate (GIR) data from glucose clamp studies and 2) a PK-PD model to estimate parameters such that the model fits the data. Assuming that the glucose clamp is perfect, we do not need to know the details of the controller in the clamp, and the GIR can be computed directly from the PK-PD model. To illustrate the procedure, we use the glucoregulatory model developed by Hovorka and modify it to have a smooth non-negative endogeneous glucose production (EGP) term. We estimate PK-PD parameters for rapid-acting insulin analogs (Fiasp and NovoRapid). We use these PK-PD parameters to illustrate GIR for insulin analogs with 30% and 50% faster absorption time than currently available rapid-acting insulin analogs. We discuss the role of system identification using GIR data from glucose clamp studies and how such identified models can be used in automated insulin dosing (AID) systems with ultra rapid-acting insulin.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。